Genmab — April 2020
-
Managing Multiple Myeloma During the COVID-19 Pandemic
A Conversation With C. Ola Landgren https://www.ascopost.com/news/april-2020/managing-multiple-myeloma-during-the-covid-19-pandemic/ -
Amivantamab er allerede på asco listen, så den er med på alm tilmelding. https://meetinglibrary.asco.org/session/12668
-
don't think, Jan van de Winkel gave up on one time milestones when he renegotiated the Arzerra deal
-
Genmab thereby got rid of participating in developement cost
-
it was in 2011 or so, when Genmab were in a very bad standing financially
-
Jeg håber og tror på at de kombinationer de afprøver er gode. Mener at have set meget opmuntrene data fra dara og bcmaxcd3 kombinationen. Hvor jeg tænkte, at daras markedspotentiale kunne være truet fordi dara kun var med i indledende behandling. Men alt det ligger noget ud i fremtiden.
-
https://clincancerres.aacrjournals.org/content/clincanres/early/2020/03/23/1078-0432.CCR-19-2299.full.pdf Nu husker jeg ikke om denne er lagt op tidligere. Men her er synergien mellem dara og BCMAxCD3 beskrevet.
-
so many articles on SC, just get it approved... https://www.reuters.com/article/multiple-myeloma-daratumumab/subcutaneous-daratumumab-effective-alternative-to-iv-formulation-for-multiple-myeloma-idUSL2N2BX1BJ
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind